Barely Significant
← all excerpts

Safety and neurochemical profiles of acute and sub-chronic oral treatment with agmatine sulfate.

Sci Rep · 2019 · PMC6722093 · PMID 31481723

Europe PMCDOI
1
hedged sentence
0.0009
closest p · 0.0× alpha
0.0009
boldest claim

The sentences

highly significantP < 0.0009actually significant
Regarding oral agmatine treatment, one-way ANOVA revealed a highly significant difference between the four dose groups ( P < 0.0009) with dose-dependent increases (2–7 folds) and higher agmatine levels at the 600 ( P < 0.01) and 900 ( P < 0.001) mg/kg doses.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.